DDInter1055 DDInter448
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) KIAA0196
KIAA0196 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Levofloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Levofloxacin {u} (Compound) causes {v} (Side Effect) Respiratory failure
Respiratory failure {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Crizotinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) KIAA0196
KIAA0196 {u} (Gene) is regulated by {v} (Gene) AXL
AXL {u} (Gene) is bound by {v} (Compound) Crizotinib
Levofloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is regulated by {v} (Gene) ABL2
ABL2 {u} (Gene) is bound by {v} (Compound) Crizotinib
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Levofloxacin (Compound) downregulates KIAA0196 (Gene) and KIAA0196 (Gene) is upregulated by Crizotinib (Compound)
Levofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Crizotinib (Compound)
Levofloxacin (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Crizotinib
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Crizotinib
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Levofloxacin (Compound) downregulates KIAA0196 (Gene) and KIAA0196 (Gene) is regulated by AXL (Gene) and AXL (Gene) is bound by Crizotinib (Compound)
Levofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is regulated by ABL2 (Gene) and ABL2 (Gene) is bound by Crizotinib (Compound)